Liu Ruoyang, Liu Yu, Zhang Long, Li Xiang, Li Ningyang, Lu Fubo, Gao Wansheng, Jia Zhankui, Huang Zhenlin, Yang Jinjian
Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Key Laboratory of Urinary Tumors, Henan Provincial Health Commission, Zhengzhou, Henan, China.
J Cell Mol Med. 2025 Feb;29(3):e70397. doi: 10.1111/jcmm.70397.
RBM6, implicated in the progression of multiple tumour types but unexplored in prostate tumours, was found to indicate potential therapeutic implications due to its elevated expression in prostate tumours. To elucidate its molecular function, scratch tests, transwell migration and invasion assays were conducted, with PCR and western blot analyses verifying molecular regulatory relationships. RNA pulldown and RNA immunoprecipitation tests were also employed to investigate underlying mechanisms. Results indicate that RBM6 enhances prostate cell migration by suppressing CDH1, yet ZEB1 overexpression alleviates this suppression. Notably, under these conditions, RBM6's inhibitory effect on MMP16 becomes more pronounced, reducing cell migration ability. Thus, under normal conditions, RBM6 promotes prostate tumour cell migration, but in the context of high ZEB1 expression, it inhibits migration. This shift in RBM6's regulatory capacity towards downstream genes underscores the importance of considering objective conditions in studying RBM6 molecules.
RBM6在多种肿瘤类型的进展中发挥作用，但在前列腺肿瘤中尚未得到研究。研究发现，RBM6在前列腺肿瘤中表达升高，具有潜在的治疗意义。为了阐明其分子功能，进行了划痕试验、Transwell迁移和侵袭试验，并通过PCR和蛋白质印迹分析验证分子调控关系。还采用RNA下拉和RNA免疫沉淀试验研究潜在机制。结果表明，RBM6通过抑制CDH1增强前列腺细胞迁移，而ZEB1的过表达减轻了这种抑制作用。值得注意的是，在这些条件下，RBM6对MMP16的抑制作用更加明显，降低了细胞迁移能力。因此，在正常条件下，RBM6促进前列腺肿瘤细胞迁移，但在ZEB1高表达的情况下，它会抑制迁移。RBM6对下游基因调控能力的这种转变突出了在研究RBM6分子时考虑客观条件的重要性。
